Luigi Di Biase
@LuigiDiBiaseMD
Followers
9K
Following
9K
Media
208
Statuses
10K
Section Head Electrophysiology, Director of Arrhythmia Services, Professor of Medicine, Albert Einstein College of Medicine at Montefiore Hospital. Views my own
New York and Austin
Joined May 2013
Excited to share our new European Heart Journal article summarizing key messages from the 2025 Consensus on Epicardial VA Ablation—covering selection, imaging, access, mapping, complications & new tools. Proud to coordinate this with @ArashArya_EP, @LuigiDiBiaseMD & team.
2
11
19
#Europace 🤝 #APHRS2025 in Yokohama!Executive Editor Prof. @LuigiDiBiaseMD representing our Journal Board 📚2 presentations and an editorial published online🌐 🙏🏻Grateful to Prof. Wataru Shimizu and the APHRS for this strong and growing collaboration with Europace and EHRA
0
10
39
I tried to tell you
19
57
323
Presented at #AHA25: In patients with atrial fibrillation after successful ablation, rivaroxaban therapy did not lead to a significantly lower incidence of a composite of stroke, systemic embolism, or new covert embolic stroke than aspirin therapy. Full OCEAN trial results:
0
163
377
OCEAN journal club kickstarter: 1.) does failure to show superiority prove statistical non-inferiority? @drjohnm 2.) delta would be magnified or same with larger sample size? ARISTOTLE had 18k patient and warfarin event rate was 1.6 % 3.) what if apixaban was used? 4.) why
nejm.org
Whether successful catheter ablation for atrial fibrillation eliminates the need for long-term oral anticoagulant therapy is unknown. We conducted an international, open-label, randomized, blinded-...
2
12
61
OCEAN just published in NEJM. In AF patients >1 yr after successful ablation, rivaroxaban did not reduce stroke/systemic embolism/new covert infarcts vs aspirin (0.31 vs 0.66 events/100 pt-yrs; P=0.28). Bleeding higher with rivaroxaban (1.6% vs 0.6%). https://t.co/AVZoOyhTqO
3
43
113
Great debate between Dr. Packer and @nmarrouche on whether PFA should be used in all HF patients… you can probably guess who won. #AHA25
0
6
14
🤔How often should we reassess stroke risk in low risk AF patients❓ Age Matters!! .. if you are older than 55 yo check this data from 🇳🇴a registry of 40K AF pts 👉
academic.oup.com
AbstractAims. Stroke risk in atrial fibrillation (AF) patients increases over time, but the optimal reassessment interval remains unclear. This study evalu
📢 Timing of stroke risk reassessment in #AF patients with a CHA2DS2-VA score of 0 or 1: the Norwegian AFNOR study 👉 https://t.co/ubGO4VJiyW
@EuropaceEiC @GiulioConte9 @Dominik_Linz @FraSantoroMD @AndyZhangMD @marcovitoloMD @DavideMei93 #Europace #arrhyhtmias #AF
0
6
9
BREAKING: #HRStv host @DanielAlyeshmer is joined by @drjohnm and @LuigiDiBiaseMD to debate the latest evidence surrounding left atrial appendage occlusion (LAAO). They review critical trials such as PROTECT, PREVAIL, and OPTION, discuss real-world data from the NCDR registry, and
2
9
28
Not too late to sign up for @AHAScience NY fellows career night tomorrow in midtown. Info on event and invited panelists in pics. @DLBHATTMD @LuigiDiBiaseMD @Drroxmehran @LouaiRazzouk @JasonKatzMD @anna_bortnick @DNFeldmanMD @GiorgioMedranda @WMCCardsFellows @SnehalPatel1410
0
8
25
Now ONLINE Vascular access & closure management for electrophysiological interventions in 2025: Clinical Consensus Statement #EHRA @escardio @HRSonline 📖 https://t.co/yq10oVCBZk
@GiulioConte9 @FraSantoroMD @marcovitoloMD
@AndyZhangMD @Dominik_Linz @DavideMei93
@LuigiDiBiaseMD
Our consensus document on vascular access for EP procedures is in print! Group effort by #EHRA, #EAPCI and #ESC CV Surgery Working Group. https://t.co/Z1CHFB4afS
1
17
39
Incredible discussions at #ElevateEP 2025 program hosted by Johnson & Johnson MedTech in Atlanta on the biophysical profiles and lesion characteristics of the Varipulse platform and the next evolution of PFA technologies from @JNJMedTech Honored to be part of the faculty,
0
6
37
@KaulMotta @LuigiDiBiaseMD You are truly lucky he is truly the best in the field
0
1
1
@HRSonline @LuigiDiBiaseMD I’m yet to find a doctor in his field who is as good as my doctor in his field @LuigiDiBiaseMD ❤️
0
1
1
Know a colleague who would be a strong voice on the HRS Board of Trustees? The Society is accepting nominations for four Board positions, including an Early Career Member, and the Treasurer/Secretary officer role. Learn more and submit your nomination: https://t.co/vJ6bKLkNvH
1
3
10
It’s a pleasure to train alongside our phenomenal team at Montefiore Health System as we continue advancing one of several cutting-edge PFA technologies being pioneered here. Today’s case marks just one of many exciting milestones ahead. (2/2)
1
2
4
Truly honored and privileged to be scrubbed in under the guidance of the legendary Professor Dr. Di Biase for his 100th VARIPULSE case since relaunch! (1/2)
3
6
42
Honored to host a packed house this weekend for the 8th Edition of @BIOTRONIK’s annual Capstone Program with Course Director, @LuigiDiBiaseMD, and our renowned faculty. Thank you to all those who joined and contributed to this impactful, industry-leading program!
0
2
12
#Europace #Epeeps Contemporary Strategies for Repeat Ablation of #AFib: A #EHRA_ESC Survey 📖 https://t.co/6Ta58Vbpzq
@GiulioConte9 @FraSantoroMD @marcovitoloMD
@AndyZhangMD @Dominik_Linz @DavideMei93
@LuigiDiBiaseMD
1
9
25
🥁#Europace #Epeeps Impact of Pulse Duration on Cardiac Electroporation: #Nanosecond #PFA favored regulated cell death and cardiomyocyte selectivity 🖨️ https://t.co/KegEYFcfTr
@GiulioConte9 @FraSantoroMD @marcovitoloMD @AndyZhangMD @Dominik_Linz @DavideMei93 @LuigiDiBiaseMD
0
10
29